EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trends in the use of proton pump inhibitors as initial therapy for gastroesophageal reflux disease in the Ohio medicaid population, 1994-1998



Trends in the use of proton pump inhibitors as initial therapy for gastroesophageal reflux disease in the Ohio medicaid population, 1994-1998



Gastroenterology. 122(4 Suppl. 1): A-196, Il



.

(PDF 0-2 workdays service: $29.90)

Accession: 035985647

Download citation: RISBibTeXText



Related references

Association of initial gastroesophageal reflux disease therapy and the costs of GERD related health services in the Ohio medicaid population. Gastroenterology 118(4 Suppl 2 Part 1): A209, April, 2000

Expenditures associated with initial therapy in Ohio medicaid patients with gastroesophageal reflux disease. Gastroenterology 122(4 Suppl 1): A-465, April, 2002

Time Trends in Physician Visits for Gastroesophageal Reflux Disease Before and After the Rx-to-OTC Switch of Proton Pump Inhibitors. Journal of Clinical Pharmacology: -, 2016

The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--clinical overview of gastroesophageal reflux disease. Roundtable discussion. Managed Care Interface Suppl B: 13-20; Discussion 24-7, 31-3, 2001

Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading?. Visceral Medicine 34(2): 110-115, 2018

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors. Digestion 76(3-4): 171-178, 2007

On-demand therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates?. Journal of Gastroenterology and Hepatology 21(Suppl. 5): S115-S118, 2006

Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. Expert Review of Pharmacoeconomics & Outcomes Research 5(1): 29-38, 2005

Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology 21(5): 883-890, 2016

Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?. American Journal of Gastroenterology 99(6): 981-988, 2004

Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors. World Journal of Gastroenterology 15(3): 334-338, 2009

Diagnosis and treatment of gastroesophageal reflux disease in Ohio Medicaid patients: practice patterns and temporal trends. Pharmacoepidemiology and Drug Safety 13(1): 21-27, 2004

Use of procedures and medications among patients with gastroesophageal reflux disease in the Ohio Medicaid population. Gastroenterology 118(4 Suppl 2 Part 1): A209, April, 2000

Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology 12(10): 1647-1655, 2015

Non response to proton pump inhibitors in gastroesophageal reflux disease. Deutsche Medizinische Wochenschrift 134(39): 1956-1956, 2009